ORBIMED ADVISORS LLC — SEC Form 4 filings
SEC reporting owner CIK 1055951. 74 Form 4 filings on record with FilingPulse; latest filed 2026-08-12.
Transaction summary — filings shown
Covers the 50 most recent of 74 filings on record, filed 2024-10-17 to 2026-08-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 22 legs across 12 filings — 22,221,614 shares, $134,835,788 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 86 legs across 30 filings — 84,110,454 shares, $175,343,231 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 53.
- Largest priced transaction: sale of 787,024 shares @ $45.38 ($35,715,149) in Enliven Therapeutics, Inc., filed 2026-06-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | Director | 11 | 1 leg · 550,000 sh · $9,900,000 | 20 legs · 1,235,000 sh · $55,674,636 | 3 |
| Enliven Therapeutics, Inc. (ELVN) | 10% owner | 2 | — | 6 legs · 1,141,531 sh · $51,683,034 | — |
| Braveheart Bio, Inc. (BRVE) | Director, 10% owner | 1 | 2 legs · 1,940,000 sh · $34,920,000 | — | 2 |
| Xtant Medical Holdings, Inc. (XTNT) | 10% owner | 1 | — | 2 legs · 73,114,592 sh · $30,708,129 | — |
| Disc Medicine, Inc. (IRON) | Director | 3 | — | 27 legs · 370,551 sh · $20,108,066 | — |
| Q32 Bio Inc. (QTTB) | Director, 10% owner | 1 | 2 legs · 1,875,000 sh · $15,000,000 | — | — |
| Scribe Therapeutics, Inc. (SCTX) | Director | 1 | 1 leg · 1,000,000 sh · $15,000,000 | — | 2 |
| Upstream Bio, Inc. (UPB) | Director, 10% owner | 1 | 2 legs · 825,000 sh · $14,025,000 | — | 6 |
| Prelude Therapeutics Inc (PRLD) | Director, 10% owner | 1 | 2 legs · 2,815,315 sh · $12,499,999 | — | — |
| Edgewise Therapeutics, Inc. (EWTX) | Director, 10% owner | 1 | 2 legs · 496,771 sh · $10,000,000 | — | — |
+14 more issuers among the filings shown — every filing appears in the table below.
Form 4 filings — ORBIMED ADVISORS LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-12 | 4 | BlossomHill Therapeutics, Inc. (BLSM) jointly with OrbiMed Capital GP VIII LLC | Conversion (C): 1,039,996 · Conversion (C): 1,049,283 · Purchase (P): 625,000 @ $16 · Conversion (C): 1,039,996 (derivative) @ $0 · Conversion (C): 1,049,283 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Braveheart Bio, Inc. (BRVE) jointly with OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC | Conversion (C): 9,132,420 · Purchase (P): 1,666,667 @ $18 · Purchase (P): 273,333 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Scribe Therapeutics, Inc. (SCTX) jointly with OrbiMed Capital GP VIII LLC | Conversion (C): 348,825 · Purchase (P): 1,000,000 @ $15 · Conversion (C): 2,065,672 (derivative) @ $0 | EDGAR |
| 2026-07-09 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Sale (S): 85,918 @ $44.86 | EDGAR |
| 2026-07-02 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Sale (S): 115,844 @ $45.50 | EDGAR |
| 2026-06-24 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC | Sale (S): 24,846 @ $45.38 · Sale (S): 1,477 @ $45 · Sale (S): 787,024 @ $45.38 · Sale (S): 46,776 @ $45 | EDGAR |
| 2026-06-17 | 4 | Enliven Therapeutics, Inc. (ELVN) jointly with OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC | Sale (S): 9,086 @ $45.02 · Sale (S): 272,322 @ $45.02 | EDGAR |
| 2026-06-15 | 4 | Shattuck Labs, Inc. (STTK) jointly with OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC | Purchase (P): 1,041,667 (derivative) · Purchase (P): 208,333 (derivative) | EDGAR |
| 2026-06-09 | 4 | Shattuck Labs, Inc. (STTK) jointly with OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC | Conversion (C): 15,366,490 (derivative) · Conversion (C): 3,073,298 (derivative) · Conversion (C): 15,366,490 (derivative) · Conversion (C): 3,073,298 (derivative) | EDGAR |
| 2026-06-01 | 4 | Q32 Bio Inc. (QTTB) jointly with OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC | Purchase (P): 1,250,000 @ $8 · Purchase (P): 625,000 @ $8 | EDGAR |
| 2026-05-29 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Sale (S): 101 @ $44.49 | EDGAR |
| 2026-05-11 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Sale (S): 48,546 @ $44.61 · Sale (S): 59,767 @ $44.58 · Sale (S): 184,639 @ $46.22 | EDGAR |
| 2026-04-28 | 4 | Traws Pharma, Inc. (TRAW) jointly with OrbiMed Capital GP VIII LLC | Purchase (P): 597,729 @ $1.67 · Purchase (P): 597,729 (derivative) · Purchase (P): 597,729 (derivative) · Purchase (P): 1,793,187 (derivative) | EDGAR |
| 2026-04-23 | 4 | Prelude Therapeutics Inc (PRLD) jointly with OrbiMed Capital GP VI LLC, ORBIMED CAPITAL LLC, OrbiMed Genesis GP LLC | Purchase (P): 1,689,189 @ $4.44 · Purchase (P): 1,126,126 @ $4.44 | EDGAR |
| 2026-04-21 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Sale (S): 52,397 @ $44.68 · Sale (S): 2,948 @ $44.52 | EDGAR |
| 2026-04-16 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Sale (S): 47,814 @ $44.51 · Sale (S): 235,863 @ $44.64 · Sale (S): 226,906 @ $45.34 | EDGAR |
| 2026-04-16 | 4 | ImageneBio, Inc. (IMA) jointly with OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC | Purchase (P): 336,603 (derivative) · Purchase (P): 384,689 (derivative) | EDGAR |
| 2026-04-09 | 4 | Adicet Bio, Inc. (ACET) jointly with OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership | Sale (S): 29,319 @ $6.53 · Sale (S): 2,400 @ $6.38 · Sale (S): 32,523 @ $6.29 · Sale (S): 40,416 @ $6.52 | EDGAR |
| 2026-02-04 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Sale (S): 1,890 @ $44.57 · Sale (S): 29,063 @ $44.58 | EDGAR |
| 2025-12-29 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Sale (S): 33,356 @ $44.55 | EDGAR |
| 2025-12-19 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Sale (S): 900 @ $44.50 · Sale (S): 100 @ $44.49 · Sale (S): 875 @ $44.49 | EDGAR |
| 2025-12-18 | 4 | Keros Therapeutics, Inc. (KROS) jointly with OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC | Disposition to issuer (D): 140,057 @ $17.75 · Disposition to issuer (D): 74,465 @ $17.75 | EDGAR |
| 2025-11-26 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Sale (S): 94,583 @ $44.54 · Sale (S): 11,890 @ $44.60 · Sale (S): 1,600 @ $44.49 | EDGAR |
| 2025-10-27 | 4 | PMV Pharmaceuticals, Inc. (PMVP) jointly with OrbiMed Capital GP V LLC | Sale (S): 1,000,000 @ $1.52 | EDGAR |
| 2025-10-10 | 4 | Adicet Bio, Inc. (ACET) jointly with OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership | Purchase (P): 1,500,000 @ $1 · Purchase (P): 3,500,000 @ $1 | EDGAR |
| 2025-09-12 | 4 | PMV Pharmaceuticals, Inc. (PMVP) jointly with OrbiMed Capital GP V LLC | Sale (S): 500,000 @ $1.80 | EDGAR |
| 2025-09-02 | 4 | Shattuck Labs, Inc. (STTK) jointly with OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC | Purchase (P): 5,255,106 @ $0.87 · Purchase (P): 1,051,021 @ $0.87 · Purchase (P): 10,111,384 (derivative) · Purchase (P): 2,022,277 (derivative) · Purchase (P): 15,366,490 (derivative) · Purchase (P): 3,073,298 (derivative) | EDGAR |
| 2025-08-12 | 4 | Turnstone Biologics Corp. (TSBX) jointly with OrbiMed Capital GP VI LLC | Code (U): 3,099,265 | EDGAR |
| 2025-07-30 | 4 | ImageneBio, Inc. (IKNA) jointly with OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC | Grant/award (A): 83,611 @ $2.49 | EDGAR |
| 2025-07-01 | 4 | Corvus Pharmaceuticals, Inc. (CRVS) jointly with OrbiMed Capital GP V LLC | Option exercise/expiry (X): 1,397,684 @ $3.50 · Sale (S): 1,176,332 @ $4.16 · Option exercise/expiry (X): 1,397,684 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Passage BIO, Inc. (PASG) jointly with OrbiMed Capital GP VII LLC | Sale (S): 231,600 @ $0.35 · Sale (S): 138,800 @ $0.33 · Sale (S): 213,257 @ $0.33 | EDGAR |
| 2025-05-16 | 4 | NeuroPace Inc (NPCE) jointly with OrbiMed Capital GP VI LLC | Sale (S): 134,136 @ $15.83 · Sale (S): 34,000 @ $15.94 | EDGAR |
| 2025-04-24 | 4 | Passage BIO, Inc. (PASG) jointly with OrbiMed Capital GP VII LLC | Sale (S): 78,049 @ $0.34 · Sale (S): 89,328 @ $0.34 · Sale (S): 68,195 @ $0.32 | EDGAR |
| 2025-04-17 | 4 | Passage BIO, Inc. (PASG) jointly with OrbiMed Capital GP VII LLC | Sale (S): 10,326 @ $0.38 · Sale (S): 61,638 @ $0.33 · Sale (S): 77,090 @ $0.33 | EDGAR |
| 2025-04-14 | 4 | Xtant Medical Holdings, Inc. (XTNT) jointly with Orbimed ROF II LLC | Sale (S): 56,004,974 @ $0.42 · Sale (S): 17,109,618 @ $0.42 | EDGAR |
| 2025-04-11 | 4 | Compass Therapeutics, Inc. (CMPX) jointly with OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC | Sale (S): 3,571,428 @ $1.59 | EDGAR |
| 2025-04-04 | 4 | Edgewise Therapeutics, Inc. (EWTX) jointly with OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC | Purchase (P): 372,578 @ $20.13 · Purchase (P): 124,193 @ $20.13 | EDGAR |
| 2025-03-26 | 4 | Disc Medicine, Inc. (IRON) jointly with OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC, OrbiMed Genesis GP LLC | Sale (S): 1,956 @ $54.11 · Sale (S): 3,026 @ $54.11 · Sale (S): 756 @ $54.11 | EDGAR |
| 2025-03-21 | 4 | Disc Medicine, Inc. (IRON) jointly with OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC, OrbiMed Genesis GP LLC | Sale (S): 13,517 @ $54.02 · Sale (S): 20,911 @ $54.02 · Sale (S): 5,228 @ $54.02 · Sale (S): 941 @ $54.01 · Sale (S): 1,457 @ $54.01 · Sale (S): 364 @ $54.01 · +3 more | EDGAR |
| 2025-03-12 | 4 | Disc Medicine, Inc. (IRON) jointly with OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC, OrbiMed Genesis GP LLC | Sale (S): 68,766 @ $54.29 · Sale (S): 106,384 @ $54.29 · Sale (S): 26,596 @ $54.29 · Sale (S): 136 @ $55.01 · Sale (S): 211 @ $55.01 · Sale (S): 53 @ $55.01 · +9 more | EDGAR |
| 2025-02-19 | 4 | MBX Biosciences, Inc. (MBX) jointly with OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC | Purchase (P): 17,962 @ $9.90 · Purchase (P): 29,540 @ $9.85 · Purchase (P): 49,070 @ $10.84 · Purchase (P): 94,100 @ $10.84 | EDGAR |
| 2025-02-10 | 4 | Sionna Therapeutics, Inc. (SION) jointly with OrbiMed Capital GP VIII LLC | Conversion (C): 3,154,959 · Purchase (P): 550,000 @ $18 · Conversion (C): 2,560,951 (derivative) @ $0 · Conversion (C): 2,048,760 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Traws Pharma, Inc. (TRAW) jointly with OrbiMed Capital GP VIII LLC | Purchase (P): 96,348 (derivative) · Purchase (P): 96,348 (derivative) | EDGAR |
| 2025-01-14 | 4 | Passage BIO, Inc. (PASG) jointly with OrbiMed Capital GP VII LLC | Sale (S): 126,209 @ $0.66 · Sale (S): 17,986 @ $0.64 · Sale (S): 79,024 @ $0.60 | EDGAR |
| 2025-01-08 | 4 | Passage BIO, Inc. (PASG) jointly with OrbiMed Capital GP VII LLC | Sale (S): 19,481 @ $0.77 · Sale (S): 52,536 @ $0.71 · Sale (S): 75,007 @ $0.68 | EDGAR |
| 2024-12-26 | 4 | Passage BIO, Inc. (PASG) jointly with OrbiMed Capital GP VII LLC | Sale (S): 230,321 @ $0.60 | EDGAR |
| 2024-12-11 | 4 | Passage BIO, Inc. (PASG) jointly with OrbiMed Capital GP VII LLC | Sale (S): 54,181 @ $0.84 · Sale (S): 8,015 @ $0.80 · Sale (S): 80 @ $0.80 | EDGAR |
| 2024-12-06 | 4 | Passage BIO, Inc. (PASG) jointly with OrbiMed Capital GP VII LLC | Sale (S): 76,200 @ $0.79 · Sale (S): 20,903 @ $0.82 | EDGAR |
| 2024-11-05 | 4 | Lomond Therapeutics Holdings, Inc. jointly with OrbiMed Capital GP VII LLC, OrbiMed Capital GP VIII LLC, OrbiMed Capital GP IX LLC | Conversion (C): 323,916 @ $3.20 · Conversion (C): 215,146 @ $3.20 · Conversion (C): 389,078 @ $3.60 · Conversion (C): 230,753 @ $3.60 · Conversion (C): 74,613 @ $3.60 · Grant/award (A): 808,894 @ $4 · +7 more | EDGAR |
| 2024-10-17 | 4 | Upstream Bio, Inc. (UPB) jointly with OrbiMed Capital GP VIII LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P. | Conversion (C): 721,956 · Purchase (P): 165,000 @ $17 · Conversion (C): 2,887,833 · Purchase (P): 660,000 @ $17 · Conversion (C): 524,500 (derivative) · Conversion (C): 2,098,000 (derivative) · +2 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1055951 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →